Meeting held on Monday, November 3, 2014 FDA hosted a discussion with Type 1 and Type 2 diabetes communities to provide FDA with real-world perspectives as the agency deliberates complex policies that affect the safety and effectiveness of marketed products on which people with diabetes depend.
To find solutions to the complex issues faced by people living with diabetes, it is critical to incorporate the perspectives of those most affected by the condition and who rely on FDA-approve/cleared products to manage diabetes.
* Please see the bottom of this webpage for presentations, biographies and a copy of the transcript.
1:00 PM - 1:05 PM
1:05 PM - 1:45 PM
Role of FDA in Diabetes:
1:45 PM - 2:15 PM
2:15 PM - 3:00 PM
FDA-Patient Dialogue Panel Discussion:
3:00 PM - 3:45 PM
Patient-FDA Dialogue Panel Discussion:
3:45 PM - 3:55 PM
Communicating with FDA:
3:55 PM - 4:00 PM
- 1:05pm - 1:45pm Role of FDA in Diabetes - Dr. Jonca Bull (PDF - 464KB)
- 1:05pm - 1:45pm Role of FDA in Diabetes - Dr. Naomi Lowy (PDF - 496KB)
1:45pm - 2:15pm Organizational Perspectives - Adam Brown(PDF - 679KB)
- 1:45pm - 2:15pm Organizational Perspectives - Dr. Maria Mupanomunda (PDF - 281KB)
3:45pm - 3:55pm Communicating with FDA - Dr. Helene Clayton-Jeter(PDF - 822KB)